Chia, C. S. B., Xu, W., & Shuyi Ng, P. (2021). A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors. ChemMedChem, 17(1). Portico. https://doi.org/10.1002/cmdc.202100576
Abstract:
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is an unprecedented global health emergency causing more than 4.2 million fatalities as of 30 July 2021. Only three antiviral therapies have been approved or granted emergency use authorization by the FDA. The SARS-CoV-2 3CL protease (3CLpro ) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis, although no inhibitors have been approved. This patent review discusses SARS coronavirus 3CLpro inhibitors that have been filed up to 30 July 2021, giving an overview on the types of inhibitors that have generated commercial interest, especially amongst drug companies. Insights into the common structural motifs required for active site binding is also discussed.
License type:
Publisher Copyright
Funding Info:
This research is supported by core funding from: Experimental Drug Development Centre
Grant Reference no. : NRF2021-IE-IECF-001
Description:
This is the peer reviewed version of the following article: Chia, C. S. B., Xu, W., & Shuyi Ng, P. (2021). A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors. ChemMedChem, 17(1). Portico. https://doi.org/10.1002/cmdc.202100576, which has been published in final form at doi.org/10.1002/cmdc.202100576. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.